Image For Activity Cover
Project ECHO: Type 1 Diabetes Care and Management
Course Description
Open to all clinicians, this program seeks to educate primary care providers, care teams, and non-diabetes specialists in best practices for type 1 diabetes care and management. With many therapeutic and pharmacological options available, clinicians need additional resources to stay up-to-date. This program, featuring live, interactive seminars and on-demand webinars, will focus on evidence-based methods for addressing type 1 diabetes with a goal of improving health-related quality-of-life for patients and empowering clinicians to provide the best possible care. The aim is to address type 1 diabetes by educating clinicians around the world in best-practices and research directly from diabetes-management specialists. There will be a total of 7 ECHOs, each focusing on a different approach to managing type 1 diabetes. 

Project ECHO started at the University of New Mexico in 2003. ECHO stands for Extension of Community Healthcare Outcomes, and it is built on the idea that while not everyone can be a specialist, all patients deserve access to specialty care. Using a hub and spoke model, and virtual platforms like Zoom, specialists are able to connect with non-specialist providers in real time to provide education and feedback on cases. Our ECHOs, which will focus on the management of type 1 diabetes, will be held on a monthly basis as live and on-demand webinars. 

This educational activity is supported by independent medical educational grants from Abbott Diabetes Care, Inc., Dexcom, Inc., Helmsley Charitable Trust, Insulet Corporation, Lilly USA LLC, Medtronic Diabetes, Novo Nordisk Inc., and Tandem Diabetes Care.
Target Audience
This program will be of substantial interest to endocrinologists and fellows caring for individuals with, or at risk for developing, type 1 diabetes and associated diseases. Additionally, this program may be of interest to primary care professionals, care teams, and advance practice professionals who treat patients with type 1 diabetes.
Learning Objectives

Upon completing this series, learners will be able to:

  • Identify new and emerging trends in type 1 diabetes management, including emerging therapeutic options;
  • Develop individualized treatment strategies, that include a variety of approaches, to manage individuals with T1D and associated comorbidities; 
  • Incorporate diabetes technologies, including insulin pump therapy and continuous glucose monitoring, into treatment strategies for appropriate individuals with T1D.
Accreditation Statement

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Endocrine Society has achieved Accreditation with Commendation.

AMA PRA Category 1 Credit
The Endocrine Society designates each activity in this course for a maximum of 7.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. While offering CME credits noted above, this program is not intended to provide extensive training or certification in the field.


Please note that while other accrediting bodies accept AMA PRA Category 1 credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.

Faculty and Disclosures

Davida Kruger, MSN, APN-BC, BC-ADM - Program Chair
Henry Ford Health System

Michael Riddell, PhD
York University

Diana Isaacs, PharmD, BC-ADM, BCPS, CDCES
Cleveland Clinic

Daniel Katselnik, MD
Diabetes and Metabolism Specialists

Ruth Weinstock, MD, PhD
SUNY Upstate Medical University

Lucia Novak, MSN, ANP-BC, BC-ADM
Capital Diabetes & Endocrine Associates

Korey Hood, PhD
Stanford University

Lorena Alarcon-Casas Wright, MD, FACE - Peer Reviewer
Univeristy of Washington School of Medicine

STATEMENT OF INDEPENDENCE
As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s guideline task force.

DISCLOSURE POLICY
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The following faculty reported relevant financial relationships: 
Davida Kruger, MSN, APN-BC, BC-ADM: 
National Institutes of Health (NIH) - Partial Salary and Benefits; Abbott, Dexcom, Eli Lilly and Company, Pendulum, Janssen, Novo Nordisk, Sanofi Aventis, Xeris - Advisory Board; Abbott, AstraZeneca, BI/Lilly, Dexcom, Xeris, Janssen, Novo Nordisk, Lilly, Valeritas - Speakers Bureau; Abbott, Novo Nordisk, Helmsley Foundation, Dexcom - Grants/Research Support to Primary Employer.
Michael Riddell, PhD: Eli Lilly, Insulet, Medtronic, Novo Nordisk - Advisory Board, Speakers Bureau; Insulet - Grant Recipient; Novo Nordisk - Clinical Trials.
Korey Hood, PhD: Dexcom, Inc - Research Support for an Investigator-Initiated Project. Lifescan Diabetes Institute, Cecelia Health, Ceracor, MedIW - Consultant Fees for Educational Content.
Diana Isaacs, PharmD, BC-ADM, BCPS, CDCES: Abbott, Dexcom, Novo Nordisck, Xeris Pharmaceuticals - Speaker; Lifescan, Companion Medical - Consultant; American Diabetes Association - Professional Practice Committee.
Daniel Katselnik, MD:  Dexcom, Novo Nordisk, AstraZeneca - Speaker; JDRF - Chapter Board Member.
Lucia Novak, MSN, ANP-BC, BC-ADM:  Abbott Diabetes Care, AstraZeneca, Janssen, Novo Nordisk, Xeris - Speaker; Abbott Diabetes Care, Novo Nordisk, Xeris, Sanofi - Consultant; Abbott Diabetes Care, Janssen, Novo Nordisk, Xeris, Sanofi - Advisor.
Ruth Weinstock, MD, PhD: NIH, JDRF, Jaeb Center for Health Research, Unitio, Helmsley Charitable Trust - Grantee; NIH - Grant Reviewer; ADA, Wolters Kluwer - Author; ADA - Speaker; Jaeb Center for Health Research - Advisory Committee; Insulet Corp, Tolerion Inc, Eli Lilly and Co, Medtronic, Diasome Pharmaceuticals, Boehringer Ingelheim, Kowa Research Institute - Participation in Multicenter Clinical Trials - all grants awarded to institution. 

Disclosure information for guest speakers is included in their individual recorded presentations.

The following peer reviewer reported no relevant financial relationships: 
Lorena Alarcon-Casas Wright, MD, FACE

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable. 


ACKNOWLEDGMENT OF COMMERCIAL SUPPORT:
This educational activity is supported by independent medical educational grants from Abbott Diabetes Care, Inc., Dexcom, Inc., Helmsley Charitable Trust, Insulet Corporation, Lilly USA LLC, Medtronic Diabetes, and Novo Nordisk Inc., Tandem Diabetes Care. 

Summary
Availability: On-Demand
Available Aug 27, 2020 to Dec 31, 2022
Cost : FREE
Credit Offered:
7 AMA PRA Category 1 Credits
7 Participation Credits
Contains: 7 Courses
Recommended
   
     EndoCareers | Contact Us | Privacy Policy | Terms of Use CONNECT WITH US                
       © 2021 Copyright Endocrine Society. All rights reserved.
2055 L Street NW, Suite 600 | Washington, DC 20036      
 202.971.3636 | 888.363.6274
      
   
Powered By